Coeptis Therapeutics Inc (COEP) Stock Analysis

Coeptis Therapeutics Inc (COEP) is a publicly traded company in the HEALTHCARE sector. It trades at $16.40. This page summarizes the public market data, fundamentals, and frequently asked questions for COEP, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $16.40

Market Sentiment

Coeptis Therapeutics Inc currently has a Neutral sentiment score of 0.03.

About Coeptis Therapeutics Inc

Coeptis Therapeutics Inc. is a biopharmaceutical company based in Wexford, Pennsylvania, dedicated to developing and commercializing innovative cancer therapies that combine brand-name and generic pharmaceuticals with advanced cell therapy platforms. By focusing on addressing unmet medical needs in oncology, Coeptis seeks to improve treatment outcomes and enhance the quality of life for cancer patients. With a robust commitment to research and development, the company is strategically positio...

GNG Research Analysis

GNG Research scores Coeptis Therapeutics Inc (COEP) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for COEP.

Frequently Asked Questions

Does COEP pay dividends?

Coeptis Therapeutics Inc (COEP) does not currently pay a regular dividend.